• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours

0
  • by alexperjescuadmin
  • in Oncology
  • — 21 Jun, 2013
Volker Heineman
Volker Heineman

CHICAGO—Adding cetuximab to first-line irinotecan chemotherapy for patients with metastatic colorectal cancer gave a median four months advantage in overall survival as compared with adding bevacizumab. Findings from the German Phase III FIRE study were presented at the 2013 meeting of the American Society of Clinical Oncology in Chicago by Professor Volker Heinemann from Munich University. He explained to Peter Goodwin why this research has clarified the clinical decision-making process for patients who have the non-mutated form of the KRAS gene and are thus sensitive to both of these targeted agents.

Share

You may also like...

  • Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014
  • ASCO Audio Journal of Oncology – September 1st, 2006 ASCO Audio Journal of Oncology – September 1st, 2006 30 Aug, 2006
  • New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer 15 Dec, 2007
  • ASCO Audio Journal of Oncology in Advance – October 15th, 2006 ASCO Audio Journal of Oncology in Advance – October 15th, 2006 14 Oct, 2006

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
  • Next story Heat shock protein inhibitor brings new hope in advanced pre-treated lung cancer
  • News

    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014
  • Related interviews

    • Second-Generation ALK Inhibitor = Longer PFS in ALK+…
    • First-Line Pembrolizumab Boosts Survival in…
    • PD-L1 Checkpoint Inhibitor Immunotherapy Boosts…
    • Nuclear War: The Facts Today
    • Lung Cancer—First-Line Checkpoint Inhibitor…
  • Home
  • Oncology
  • Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours

© COPYRIGHT 2013 AUDIOMEDICA.COM.